Valuation: Everest Organics Limited

Market Cap 2.44B 25.47M 22.07M 20.86M 18.94M 35.49M 35.71M 249M 96.23M 1.24B 95.67M 93.55M 3.95B P/E 2025
-190x
P/E 2026 35.7x
Enterprise Value 2.94B 30.61M 26.52M 25.07M 22.76M 42.65M 42.91M 299M 116M 1.49B 115M 112M 4.75B EV / Sales 2025
1.79x
EV / Sales 2026 1.25x
Free-Float
23.1%
Yield 2025 *
-
Yield 2026 -
1 day+0.10%
1 week-7.02%
Current month-8.12%
1 month-12.94%
3 months-2.40%
6 months-11.08%
Current year-50.26%
1 week 244
Extreme 244
283.95
1 month 244
Extreme 244
333
Current year 197
Extreme 197
536.4
1 year 197
Extreme 197
536.4
3 years 110
Extreme 110
536.4
5 years 95
Extreme 95
536.4
10 years 44.45
Extreme 44.45
536.4
Manager TitleAgeSince
Chief Executive Officer 48 -
Director of Finance/CFO 59 27/09/2015
Director TitleAgeSince
Director/Board Member 47 28/09/2007
Director/Board Member 48 29/07/2014
Director/Board Member 71 12/11/2024
Change 5-day change 1-year change 3-year change Capi.($)
+0.10%-7.02%-41.35%+115.69% 25.44M
+1.01%-1.72%+15.70%+61.20% 45.9B
-4.55%-7.58%+28.20%+96.63% 38.7B
+0.77%-3.32%+6.81%+71.61% 11.43B
+0.52%-1.88%-12.29%+9.92% 11.38B
+0.77%+0.77%+20.74%+148.34% 9.09B
-0.47%+0.16%+27.34%+36.14% 7.3B
+1.61%-2.61%+14.79%+181.38% 6.98B
-1.00%-3.90%+34.92%-20.68% 7.13B
+0.61%-4.18%-43.92%+5.23% 4.89B
Average -0.11%-2.02%+5.09%+70.55% 14.28B
Weighted average by Cap. -0.76%-2.57%+15.93%+71.69%

Financials

2025 2026
Net sales 1.6B 16.67M 14.45M 13.66M 12.4M 23.24M 23.38M 163M 63M 811M 62.63M 61.24M 2.59B 1.97B 20.5M 17.77M 16.79M 15.25M 28.58M 28.75M 200M 77.47M 998M 77.02M 75.31M 3.18B
Net income -12.9M -135K -117K -110K -100K -187K -189K -1.32M -508K -6.54M -505K -494K -20.86M 55.46M 578K 501K 474K 430K 806K 811K 5.65M 2.18M 28.13M 2.17M 2.12M 89.67M
Net Debt 412M 4.3M 3.73M 3.52M 3.2M 5.99M 6.03M 42.03M 16.24M 209M 16.15M 15.79M 667M 493M 5.14M 4.45M 4.21M 3.82M 7.16M 7.2M 50.24M 19.41M 250M 19.3M 18.87M 797M
Logo Everest Organics Limited
Everest Organics Limited is engaged in the business of manufacturing of active pharmaceutical ingredients (API) and intermediaries. It is involved in the manufacturing of bulk drugs. The Company’s API products include Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Tamsulosin Hcl, and Dexlansoprazole. Its products under development include Remdesivir, Molnupiravir, Carbidopa, Acotiamide HCL, and Apixaban. Its intermediates products include Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5-Thiazolecarboxylate, Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate, Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate, 2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride, and 5-(1H-Pyroll-1-yl)-2-Mercaptobenzimidazole, among others.
Employees
316
Date Price Change Volume
16/09/26 251.60 +0.10% 2,903
15/09/26 ₹251.35 -5.19% 2,988
11/09/26 ₹265.10 -3.60% 909
10/09/26 ₹275.00 +0.75% 1,179
09/09/26 ₹272.95 +0.87% 1,865
  1. Stock Market
  2. Stocks
  3. EVERESTO6 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!